

02 愛滋病毒治療副作用之處置

Black Box Warning---Abacavir

1. Serious and sometimes fatal hypersensitivity reactions
2. Lactic acidosis and severe hepatomegaly with steatosis (NRTI)

Black Box Warning---Didanosine

1. Fatal and nonfatal pancreatitis alone or in combination with other ART
2. Fatal lactic acidosis has been reported in pregnant women (avoid ddI+d4T in pregnant women)
3. Lactic acidosis and severe hepatomegaly with steatosis (NRTI)

Black Box Warning---Lamivudine (3TC)

1. Lactic acidosis and severe hepatomegaly with steatosis (NRTI)
2. Severe acute exacerbation of HBV infection have been reported in HBV/HIV coinfecting upon discontinuation of 3TC-containing products.
3. Hepatic function should be monitored closely with both clinical and lab follow-up for at least several months after discontinuation of 3TC in patient with HBV/HIV coinfection.

Black Box Warning---Stavudine (d4T)

1. Lactic acidosis and severe hepatomegaly with steatosis (NRTI)
2. Fatal lactic acidosis has been reported among pregnant women who received combination of d4T and ddI with other ART
3. Fatal and non-fatal pancreatitis have occurred when d4T+ddI with or without hydroxyurea

Black Box Warning---Tenofovir (TDF)

1. Lactic acidosis and severe hepatomegaly with steatosis (NtRTI)
2. Severe acute exacerbation of hepatitis B have been reported in patients who discontinued TDF
3. Hepatic function should be monitored closely with both clinical and lab follow-up for at least several months after discontinuation of 3TC in patient with HBV/HIV co-infection.

Black Box Warning---Zidovudine (AZT)

1. Associated with symptomatic myopathy
2. Lactic acidosis and severe hepatomegaly with steatosis (NRTI)

Black Box Warning---Nevirapine

1. Severe, life-threatening and in some cases fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure.
2. Severe life-threatening hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction have occurred with NVP

treatment

3. Monitored during the first 18 weeks of therapy
4. A 14-day lead-in period should be followed strictly
5. No restart after severe hepatic, skin or hypersensitivity reactions

Black Box Warning---Ritonavir

- Coadministration of ritonavir with certain non-sedating antihistamines, sedative hypnotics, antiarrhythmics, or ergot alkalids may result in potentially serious or life-threatening adverse events

Black Box Warning---Tipranavir

1. TPV/RTV has been associated with reports of both fatal and non-fatal intracranial hemorrhage, clinical hepatitis and hepatic decompensation
2. Extra vigilance is warranted in patients with chronic HBV/HIV or HCV/HIV coinfection

Black Box Warning---Maraviroc

- Hepatotoxicity has been reported with maraviroc and may be preceded by evidence of a systemic allergic reaction (e.g., pruritic rash, eosinophilia, or elevated IgE)